Acquired QT interval prolongation and HERG: Implications for drug discovery and development

European Journal of Pharmacology

Volumn 500, Issue 1-3 SPEC. ISS., 2004, Pages 129-142

  Finlayson, Keith ^a   Witchel, Harry J ^b   McCulloch, James ^a   Sharkey, John ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Drug discovery; HERG protein; High throughput screening; Iatrogenic disease; Long QT syndrome; Torsades de Pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIESTROGEN; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CALCIUM ANTAGONIST; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; DOFETILIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; PIMOZIDE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PSYCHOTROPIC AGENT; RUBIDIUM 86; SEROTONIN UPTAKE INHIBITOR; TERFENADINE;

ANALYTIC METHOD; BINDING ASSAY; COMPUTER MODEL; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FAMILIAL DISEASE; FLUORESCENCE; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; HEART MUSCLE POTENTIAL; HUMAN; INCIDENCE; LIGAND BINDING; LONG QT SYNDROME; NONHUMAN; POTASSIUM CURRENT; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SUDDEN DEATH; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HUMANS; LONG QT SYNDROME; MODELS, MOLECULAR; MUTATION; PHARMACEUTICAL PREPARATIONS; POTASSIUM CHANNELS, VOLTAGE-GATED; TORSADES DE POINTES;

EID: 4644276334     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.019     Document Type: Review

References (108)

1. G.W. Abbott, F. Sesti, I. Splawski, M.E. Buck, M.H. Lehmann, K.W. Timothy, M.T. Keating, and S.A. Goldstein MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia Cell 97 2 1999 175 187
2. K. Angelo, Y.V. Korolkova, M. Grunnet, E.V. Grishin, K.A. Pluzhnikov, D.A. Klaerke, H.G. Knaus, M. Moller, and S.P. Oleson A radiolabelled peptide ligand of the hERG channel, [(125I)]-BeKm-1 Pflugers Arch. Eur. J. Physiol. 477 1 2003 55 63
3. C. Antzelevitch, and W. Shimizu Cellular mechanisms underlying the long QT syndrome Curr. Opin. Cardiol. 17 1 2002 43 51
4. M.A. Arsenian Magnesium and cardiovascular disease Prog. Cardiovasc. Dis. 35 4 1993 271 310
5. J. Barhanin, F. Lesage, E. Guillemare, M. Fink, M. Lazdunski, and G. Romey K(V)LQT1 and IsK (mink) proteins associate to form the I(Ks) cardiac potassium current Nature 384 6604 1996 78 80
6. J.B. Barlow, C.K. Bosman, and J.W. Cochrane Congenital cardiac arrhythmia Lancet II 1964 531
7. D.F. Baxter, M. Kirk, A.F. Garcia, A. Raimondi, M.H. Holmqvist, K.K. Flint, D. Bojanic, P.S. Distefano, R. Curtis, and Y. Xie A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels J. Biomol. Screen. 7 2002 79 85
8. L. Belardinelli, C. Antzelevitch, and M.A. Vos Assessing predictors of drug-induced torsade de pointes Trends Pharmacol. Sci. 24 12 2003 619 625
9. P.B. Bennett, and H.R. Guthrie Trends in ion channel drug discovery: advances in screening technologies Trends Biotechnol. 21 12 2003 563 569
10. G. Bode, K. Olejniczak Expert Working Group ICH Topic: The draft ICH S7B step 2: note for guidance on safety pharmacology studies for human pharmaceuticals Fundam. Clin. Pharmacol. 16 2 2002 105 118
11. A. Cavalli, E. Poluzzi, F. De Ponti, and M. Recanatini Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers J. Med. Chem. 45 18 2002 3844 3853
12. C.S. Cheng, D. Alderman, J. Kwash, J. Dessaint, R. Patel, M.K. Lesco, M.B. Kinrade, and W. Yu A high-throughput HERG potassium channel function assay: an old assay with a new look Drug Dev. Ind. Pharm. 28 2 2002 177 191
13. W.J. Crumb, and I. Cavero QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development Pharm. Sci. Technol. Today 2 7 1999 270 280
14. M.E. Curran, I. Splawski, K.W. Timothy, G.M. Vincent, E.D. Green, and M.T. Keating A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome Cell 80 5 1995 795 803
15. D.S. D'Aunno, A.H. Dougherty, H.F. De Block, and J.V. Meck Effect of short- and long-duration spaceflight on QTc intervals in healthy astronauts Am. J. Cardiol. 91 2003 494 497
16. B. Darpo Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes Eur. Heart J. 3 2001 K70 K80 (Suppl.)
17. P. Davey Influence of posture and handgrip on the QT interval in left ventricular hypertrophy and in chronic heart failure Clin. Sci. 96 1999 403 407
18. A.S. Davis The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods Human Exp. Toxicol. 17 12 1998 677 680
19. F. De Clerck, A. Van de Water, J. D'Aubioul, H.R. Lu, K. Van Rossem, A. Hermans, and K. Van Ammel In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity Fundam. Clin. Pharmacol. 16 2 2002 125 140
20. F. De Ponti, E. Poluzzi, and N. Montanaro QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience Eur. J. Clin. Pharmacol. 56 2000 1 18
21. F. De Ponti, E. Poluzzi, A. Cavalli, M. Recanatini, and N. Montanaro Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview Drug Safety 25 4 2002 263 286
22. F. Dessertenne Ventricular tachycardia with 2 variable opposing foci Arch. Mal. Coeur. Vaiss. 59 2 1966 263 272
23. J.M. Di Diego, L. Belardinelli, and C. Antzelevitch Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation Circulation 108 8 2003 1027 1033
24. S. Diochot, E. Loret, T. Bruhn, L. Beress, and M. Lazdunski APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels Mol. Pharmacol. 64 1 2003 59 69
25. D.A. Doyle, J. Morais Cabral, R.A. Pfuetzner, A. Kuo, J.M. Gulbis, S.L. Cohen, B.T. Chait, and R. MacKinnon The structure of the potassium channel: molecular basis of K+ conduction and selectivity Science 280 5360 1998 69 77
26. L. Eckardt, W. Haverkamp, M. Borggrefe, and G. Breithardt Experimental models of torsade de pointes Cardiovasc. Res. 39 1 1998 178 193
27. S. Ekins, W.J. Crumb, R.D. Sarazan, J.H. Wikel, and S.A. Wrighton Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel J. Pharmacol. Exp. Ther. 301 2 2002 427 434
28. B. Fermini, and A.A. Fossa The impact of drug-induced QT interval prolongation on drug discovery and development Nat. Rev., Drug Discov. 2 6 2003 439 447
29. K. Finlayson, and J. Sharkey A high-throughput binding assay for HERG Z. Yan G.W. Caldwell Methods in Pharmacology and Toxicology Optimization in Drug Discovery: In Vitro Methods 2004 Humana Press Totowa, NJ 353 368
30. 3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen Eur. J. Pharmacol. 430 1 2001 147 148
31. 3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? Eur. J. Pharmacol. 412 2001 203 212
32. A.A. Fossa, T. Wisialowski, E. Wolfgang, E. Wang, M. Avery, D.L. Raunig, and B. Fermini Differential effect of HERG blocking agents on cardiac electrical alterans in the guinea pig Eur. J. Pharmacol. 486 2 2004 209 221
33. M.E. Fraley, K.L. Arrington, C.A. Buser, P.A. Ciecko, K.E. Coll, C. Fernandes, G.D. Hartman, W.F. Hoffman, J.J. Lynch, R.C. McFall, K. Rickert, R. Singh, S. Smith, K.A. Thomas, and B.K. Wong Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl group on pharmacokinetics and hERG binding Bioorg. Med. Chem. Lett. 14 2004 351 355
34. R.W. Friesen, Y. Ducharme, R.G. Ball, M. Blouin, L. Boulet, B. Cote, R. Frenette, M. Girard, D. Guay, Z. Huang, T.R. Jones, F. Laliberte, J.J. Lynch, J. Mancini, E. Martins, P. Masson, E. Muise, D.J. Pon, P.K. Siegl, A. Styhler, N.N. Tsou, M.J. Turner, R.N. Young, and Y. Girard Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity J. Med. Chem. 46 12 2003 2413 2426
35. L.A. Garza, R.L. Vick, J.J. Nora, and D.G. McNamara Heritable Q-T prolongation without deafness Circulation 41 1 1970 39 48
36. S. Gill, J. Gill, S.S. Lee, C. Hesketh, D. Fedida, S. Rezazadeh, L. Stankovich, and D. Liang Flux assays in high throughput screening of ion channels in drug discovery Assay Drug Dev. Technol. 1 5 2003 709 717
37. R.F. Gilmour A novel approach to identifying antiarrhythmic drug targets Drug Discov. Today 8 4 2003 162 167
38. M.R. Gralinski The dog's role in the preclinical assessment of QT interval prolongation Toxicol. Pathol. 31 2003 11 16 (Suppl.)
39. J.C. Hancox, A.J. Levi, and H.J. Witchel Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential Pflugers Arch. 436 6 1998 843 853
40. J.C. Hancox, K.C. Patel, and J.V. Jones Antiarrhythmics - from cell to clinic; past, present, and future Heart 84 1 2000 14 24
41. W. Haverkamp, G. Breithardt, A.J. Camm, M.J. Janse, M.R. Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, and R. Shah The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications Eur. Heart J. 21 15 2000 1216 1231
42. J.A. Henry Epidemiology and relative toxicity of antidepressant drugs in overdose Drug Safety 16 6 1997 374 390
43. L.M. Hondeghem, and P. Hoffman Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability J. Cardiovasc. Pharmacol. 41 1 2003 14 24
44. L.M. Hondeghem, L. Carlsson, and G. Duker Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic Circulation 103 15 2001 2004 2013
45. L.M. Hondeghem, H.R. Lu, K. van Rossem, and F. De Clerck Detection of proarrhythmia in the female rabbit heart: blinded validation J. Cardiovasc. Electrophysiol. 14 2003 287 294
46. E. Isacoff, D. Papazian, L. Timpe, Y.N. Jan, and L.Y. Jan Molecular studies of voltage-gated potassium channels Cold Spring Harbor Symp. Quant. Biol. 55 1990 9 17
47. A.F. Jervell, and F. Lange-Nielsen Congenital deaf mutism: functional heart disease with prolongation of the Q-T interval and sudden death Am. Heart J. 54 1 1957 59 68
48. Y. Jiang, A. Lee, J. Chen, M. Cadene, B.T. Chait, and R. MacKinnon The open conformation of potassium channels Nature 417 2002 523 526
49. G.M. Keseru Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods Bioorg. Med. Chem. Lett. 13 16 2003 2773 2775
50. L. Kiss, P.B. Bennett, V.N. Uebele, K.S. Koblan, S.A. Kane, B. Neagle, and K. Schroeder High throughput ion-channel pharmacology: planar-array-based voltage clamp Assay Drug Dev. Technol. 1 1-2 2003 127 135
51. R.J. Lukas, J.D. Fryer, J.B. Eaton, and C.L. Gentry Some methods for studies of nicotinic acetylcholine receptor pharmacology E.D. Levin Nicotinic Receptors and the Nervous System 2002 CRC Press Boca Raton 3 27
52. R. Mackinnon Determination of the subunit stoichiometry of a voltage-activated potassium channel Nature 350 6315 1991 232 235
53. A.A. Magnoni, M.T. Kinirons, C.G. Swift, and S.H.D. Jackson Impact of age on QT interval and QT dispersion in healthy subjects; a regression analysis Age Ageing 32 2003 326 331
54. M. Malik, and A.J. Camm Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling Drug Safety 24 5 2001 323 351
55. F.L., Meissner, 1856. AnonymousTaubstummheir und Taubstummenbildung. Leipzig and Heidelberg, 120.
56. D.J. Milan, T.A. Peterson, J.N. Ruskin, R.T. Peterson, and C.A. MacRae Drugs that induce repolarization abnormalities cause bradycardia in zebrafish Circulation 107 10 2003 1355 1358
57. J.T. Milnes, C.E. Dempsey, J.M. Ridley, O. Crociani, A. Arcangeli, J.C. Hancox, and H.J. Witchel Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin FEBS Lett. 547 1-3 2003 20 26
58. J.S. Mitcheson, and M.D. Perry Molecular determinants of high-affinity drug binding to HERG channels Curr. Opin. Drug Discov. Dev. 6 5 2003 667 674
59. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, and M.C. Sanguinetti A structural basis for drug-induced long QT syndrome Proc. Natl. Acad. Sci. U. S. A. 97 2000 12329 12333
60. J. Molnar, F. Zhang, J. Weiss, F.A. Ehlert, and J.E. Rosenthal Diurnal pattern of QTc interval: how long is prolonged? J. Am. Coll. Cardiol. 27 1 1996 76 83
61. J.H. Morais Cabral, A. Lee, S.L. Cohen, B.T. Chait, M. Li, and R. Mackinnon Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain Cell 95 5 1998 649 655
62. J. Morganroth A definitive or thorough phase I QT ECG trial as a requirement for drug safety assessment J. Electrocardiol. 37 1 2004 25 29
63. A.J. Moss, P.J. Schwartz, R.S. Crampton, E.H. Locati, and E. Carleen The Long QT Syndrome: a prospective international study Circulation 71 1 1985 80 89
64. A.J. Moss, P.J. Schwartz, R.S. Crampton, D. Tzivoni, E.H. Locati, J. MacCluer, W.J. Hall, L. Weitkamp, G.M. Vincent, A. Garson, J. Robinson, J. Benhorin, and S. Choi The long QT syndrome: prospective longitudinal study of 328 families Circulation 84 3 1991 1136 1144
65. R. Netzer, A. Ebneth, U. Bischoff, and O. Pongs Screening lead compounds for QT interval prolongation Drug Discov. Today 6 2 2001 78 84
66. R. Netzer, U. Bischoff, and A. Ebneth HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery Curr. Opin. Drug Discov. Dev. 6 4 2003 462 469
67. B. Paltoo, S. O'Donoghue, and M.S. Mousavi Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval J. Pacing Clin. Electrophysiol. 24 2001 895 897
68. D.M. Papazian, T.L. Schwarz, B.L. Tempel, Y.N. Jan, and L.Y. Jan Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila Science 237 4816 1987 749 753
69. L. Pardo-Lopez, M. Zhang, J. Liu, M. Jiang, L.D. Possani, and G.N. Tseng Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule J. Biol. Chem. 277 19 2002 16403 16411
70. A.D. Paulussen, R.A. Gilissen, M. Armstrong, P.A. Doevendans, P. Verhasselt, H.J. Smeets, E. Schulze-Bahr, W. Haverkamp, G. Breithardt, N. Cohen, and J. Aerssens Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients J. Mol. Med. 82 3 2004 182 188
71. R.A. Pearlstein, R. Vaz, and D. Rampe Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel; a model for bad behaviour J. Med. Chem. 46 11 2003 2017 2022
72. M. Personne, H. Persson, and E. Sjoberg Citalopram toxicity Lancet 350 1997 518 519
73. P.E. Puddu, A. Criniti, and F. Monti Screening for drug-induced (acquired) long QT syndrome: is it time to apply new methods? Eur. Heart J. 22 5 2001 363 369
74. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 1 2003 32 45
75. O. Roche, G. Trube, J. Zuegge, P. Pflimlin, A. Alanine, and G. Schneider A virtual screening method for prediction of the HERG potassium channel liability of compound libraries ChemBioChem 3 5 2002 455 459
76. C. Romano Congenital cardiac arrhythmia Lancet 17 1965 658 659
77. M.C. Sanguinetti, and M.T. Keating Role of delayed rectifier potassium channels in cardiac repolarisation and arrhythmias News Physiol. Sci. 12 1997 152 157
78. M.C. Sanguinetti, C. Jiang, M.E. Curran, and M.T. Keating A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel Cell 81 2 1995 299 307
79. M.C. Sanguinetti, M.E. Curran, A. Zou, J. Shen, P.S. Spector, D.L. Atkinson, and M.T. Keating Coassembly of K(V)LQT1 and minK (IsK) proteins to form I(Ks) potassium channel Nature 384 6604 1996 80 83
80. C.W. Scott, D.E. Wilkins, S. Trivedi, and D.J. Crankshaw A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry Anal. Biochem. 319 2 2003 251 257
81. R. Schonherr, and S.H. Heinemann Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel J. Physiol. 493 3 1996 635 642
82. E.G. Schouten, J.M. Dekker, P. Meppelink, F.J. Kok, J.P. Vandenbrouke, and J. Pool QT interval prolongation predicts cardiovascular mortality in an apparently healthy population Circulation 84 4 1991 1516 1523
83. R.R. Shah The significance of QT interval in drug development Br. J. Clin. Pharmacol. 54 2 2002 188 202
84. I. Splawski, M. Tristani-Firouzu, M.H. Lehmann, M.C. Sanguinetti, and M.T. Keating Mutations in the hmink gene cause long QT syndrome and suppress IKs function Nat. Genet. 17 3 1997 338 340
85. W. Tang, J. Kang, X. Wu, D. Rampe, L. Wang, H. Shen, Z. Li, D. Dunnington, and T. Garyantes Development and evaluation of high throughput functional assay methods for hERG potassium channel J. Biomol. Screen. 6 5 2001 325 331
86. G.C. Terstappen Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay Anal. Biochem. 272 2 1999 149 155
87. M.B. Thomsen, P.G. Volders, M. Stengl, R.L. Spatjens, J.D. Beekman, U. Bischoff, M.A. Kall, K. Frederiksen, J. Matz, and M.A. Vos Electrophysiological safety of sertindole in dogs with normal and remodelled hearts J. Pharmacol. Exp. Ther. 307 2 2003 776 784
88. X.-L. Tian, S.L. Yong, X. Wan, L. Wu, M.K. Chung, P.J. Tchou, D.S. Rosenbaum, D.R. Van Wagoner, G.E. Kirsch, and Q. Wang Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo Cardiovasc. Res. 61 2 2004 256 267
89. J.I. Vandenberg, B.D. Walker, and T.J. Campbell HERG K+ channels: friend and foe Trends Pharmacol. Sci. 22 5 2001 240 246
90. G.M. Vincent, K.W. Timothy, M. Leppert, and M. Keating The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome N. Engl. J. Med. 327 12 1992 846 852
91. W.A. Volberg, B.J. Koci, W. Su, J. Lin, and Z. Zhou Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics J. Pharmacol. Exp. Ther. 302 1 2002 320 327
92. I.D. Wakefield, C. Pollard, W.S. Redfern, T.G. Hammond, and J.P. Valentin The application of in vitro methods to safety pharmacology Fundam. Clin. Pharmacol. 16 3 2002 209 218
93. B.D. Walker, A.D. Krahn, G.J. Klein, A.C. Skanes, J. Wang, R. Hegele, and R. Yee Congenital and acquired long QT syndromes Can. J. Cardiol. 19 1 2003 76 87
94. Q. Wang, J. Shen, I. Splawski, D.L. Atkinson, Z. Li, J.L. Robinson, A. Moss, J.A. Towbin, and M.T. Keating SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome Cell 80 5 1995 805 811
95. Q. Wang, M.E. Curran, I. Splawski, T.C. Burn, J.M. Millholland, T.J. Van Raay, J. Shen, K.W. Timothy, G.M. Vincent, T. de Jager, P.J. Schwartz, J.A. Towbin, A.J. Moss, D.L. Atkinson, G.M. Landes, T.D. Connors, and M.T. Keating Positional cloning of a novel potassium channel gene: KvLQT1 mutations cause cardiac arrhythmias Nat. Genet. 12 1 1996 17 23
96. J. Wang, K. Della-Penna, H. Wang, J. Karczewski, T.M. Connolly, K.S. Koblan, P.B. Bennett, and J.J. Salata Functional and pharmacological properties of canine ERG potassium channels Am. J. Physiol, Heart Circ. Physiol. 284 1 2003 H256 H267
97. O.C. Ward A new familial cardiac syndrome in children J. Ir. Med. 54 1964 103 106
98. J.W. Warmke, and B. Ganetzky A family of potassium channel genes related to eag in Drosophila and mammals Proc. Natl. Acad. Sci. U. S. A. 91 8 1994 3438 3442
99. R. Webster, D. Leishman, and D. Walker Towards a drug concentration effect relationship for QT prolongation and torsades de pointes Curr. Opin. Drug Discov. Dev. 5 2002 116 126
100. H.J. Witchel, J.T. Milnes, J.S. Mitcheson, and J.C. Hancox Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes J. Pharmacol. Toxicol. Methods 48 2 2002 65 80
101. H.J. Witchel, V.K. Pabbathi, G. Hofmann, A.A. Paul, and J.C. Hancox Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents FEBS Lett. 512 2002 59 66
102. H.J. Witchel, J.C. Hancox, and D.J. Nutt Psychotropic drugs, cardiac arrhythmia, and sudden death J. Clin. Psychopharmacol. 23 1 2003 58 77
103. J.Y. Wu, and S.L. Lipsius Effects of extracellular Mg2+ on T- and L-type Ca2+ currents in single atrial myocytes Am. J. Physiol. 259 6 pt 2 1990 H1842 H1850
104. R.S. Wymore, G.A. Gintant, R.T. Wymore, J.E. Dixon, D. McKinnon, and I.S. Cohen Tissue and species distribution of mRNA for the IKr-like K+ channel, erg Circ. Res. 80 2 1997 261 268
105. T. Yang, D. Snyders, and D.M. Roden Drug block of IKr: model systems and relevance to human arrhythmias J. Cardiovasc. Pharmacol. 38 5 2001 737 744
106. P. Yang, H. Kanki, B. Drolet, T. Yang, J. Wei, P.C. Viswanathan, S.H. Hohnloser, W. Shimizu, P.J. Schwartz, M. Stanton, K.T. Murray, K. Norris, A.L. George, and D.M. Roden Allelic variants in long-QT disease genes in patients with drug-associated torsades de points Circulation 105 16 2002 1943 1948
107. M. Zehender, S. Hohnloser, and H. Just QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards Cardiovasc. Drugs Ther. 5 1991 515 530
108. Z. Zhou, Q. Gong, B. Ye, Z. Fan, J.C. Makielski, G.A. Robertson, and C.T. January Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature Biophys. J. 74 1 1998 230 241